Maravai LifeSciences Holdings, Inc. (MRVI)
MRVI Stock Price Chart
Explore Maravai LifeSciences Holdings, Inc. interactive price chart. Choose custom timeframes to analyze MRVI price movements and trends.
MRVI Company Profile
Discover essential business fundamentals and corporate details for Maravai LifeSciences Holdings, Inc. (MRVI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Nov 2020
Employees
570.00
Website
https://www.maravai.comCEO
William E. Martin III
Description
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
MRVI Financial Timeline
Browse a chronological timeline of Maravai LifeSciences Holdings, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.06, while revenue estimate is $48.73M.
Earnings released on 11 Aug 2025
EPS came in at -$0.08 falling short of the estimated -$0.06 by -33.33%, while revenue for the quarter reached $47.40M , missing expectations by -5.36%.
Earnings released on 12 May 2025
EPS came in at -$0.08 falling short of the estimated -$0.07 by -14.29%, while revenue for the quarter reached $46.85M , beating expectations by +6.46%.
Earnings released on 18 Mar 2025
EPS came in at -$0.06 falling short of the estimated -$0.03 by -100.00%, while revenue for the quarter reached $56.41M , missing expectations by -2.39%.
Earnings released on 7 Nov 2024
EPS came in at -$0.02 falling short of the estimated -$0.01 by -150.00%, while revenue for the quarter reached $65.20M , beating expectations by +15.10%.
Earnings released on 7 Aug 2024
EPS came in at -$0.08 falling short of the estimated -$0.04 by -100.00%, while revenue for the quarter reached $73.40M , beating expectations by +2.47%.
Earnings released on 8 May 2024
EPS came in at -$0.02 falling short of the estimated -$0.02 by -21.43%, while revenue for the quarter reached $64.18M , beating expectations by +5.99%.
Earnings released on 22 Feb 2024
EPS came in at $0.01 surpassing the estimated $0.00 by +184.90%, while revenue for the quarter reached $74.14M , beating expectations by +15.16%.
Earnings released on 7 Nov 2023
EPS came in at -$0.01 falling short of the estimated -$0.00 by -257.14%, while revenue for the quarter reached $66.87M , missing expectations by -11.46%.
Earnings released on 7 Aug 2023
EPS came in at -$0.06 falling short of the estimated -$0.03 by -100.00%, while revenue for the quarter reached $68.91M , missing expectations by -3.12%.
Earnings released on 8 May 2023
EPS came in at $0.03 falling short of the estimated $0.04 by -17.24%, while revenue for the quarter reached $79.03M , missing expectations by -0.87%.
Earnings released on 22 Feb 2023
EPS came in at $0.35 surpassing the estimated $0.34 by +2.94%, while revenue for the quarter reached $204.71M , missing expectations by -0.10%.
Earnings released on 2 Nov 2022
EPS came in at $0.37 surpassing the estimated $0.32 by +15.62%, while revenue for the quarter reached $191.26M , missing expectations by -1.97%.
Earnings released on 4 Aug 2022
EPS came in at $0.54 surpassing the estimated $0.45 by +20.00%, while revenue for the quarter reached $242.73M , beating expectations by +4.08%.
Earnings released on 5 May 2022
EPS came in at $0.54 surpassing the estimated $0.44 by +22.73%, while revenue for the quarter reached $244.29M , beating expectations by +5.17%.
Earnings released on 23 Feb 2022
EPS came in at $0.45 surpassing the estimated $0.38 by +18.42%, while revenue for the quarter reached $228.44M , beating expectations by +9.78%.
Earnings released on 10 Nov 2021
EPS came in at $0.44 surpassing the estimated $0.35 by +25.71%, while revenue for the quarter reached $204.81M , beating expectations by +34.62%.
Earnings released on 10 Aug 2021
EPS came in at $0.44 surpassing the estimated $0.32 by +37.50%, while revenue for the quarter reached $217.78M , beating expectations by +11.79%.
Earnings released on 10 May 2021
EPS came in at $0.26 surpassing the estimated $0.21 by +23.81%, while revenue for the quarter reached $148.21M , beating expectations by +31.25%.
Earnings released on 2 Mar 2021
EPS came in at $0.13 surpassing the estimated $0.12 by +8.33%, while revenue for the quarter reached $98.35M .
Earnings released on 23 Nov 2020
EPS came in at $0.00 , while revenue for the quarter reached $46.91M .
Earnings released on 30 Sept 2020
EPS came in at $0.44 , while revenue for the quarter reached $87.86M .
MRVI Stock Performance
Access detailed MRVI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.